The RPN1 antibody targets Ribophorin I (RPN1), a key component of the oligosaccharyltransferase (OST) complex located in the endoplasmic reticulum (ER). RPN1. a type I transmembrane glycoprotein, plays a critical role in N-linked glycosylation, a post-translational modification essential for protein folding, quality control, and cellular trafficking. It facilitates the recognition of nascent polypeptide chains and the transfer of preassembled oligosaccharides to specific asparagine residues. Dysregulation of RPN1 has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic syndromes, due to its impact on protein homeostasis and ER stress responses.
RPN1 antibodies are widely used in research to study ER-associated processes, such as glycosylation efficiency, ER stress pathways, and secretory protein maturation. They are employed in techniques like Western blotting, immunofluorescence, and immunoprecipitation to detect RPN1 expression, localization, and interactions within the OST complex. In cancer biology, RPN1 antibodies help investigate tumor progression mechanisms linked to aberrant glycosylation and metastasis. Additionally, these tools aid in exploring therapeutic strategies targeting ER dysfunction in conditions like diabetes or Alzheimer’s disease. The development and validation of RPN1-specific antibodies remain crucial for advancing our understanding of cellular proteostasis and disease pathogenesis.